Hjem › T-celle-lymfom › New York › New York City
Kliniske studier for T-celle-lymfom i New York City, NY
13 studier for T-celle-lymfom søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RekruttererFase 1
- Columbia University, New York
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RekruttererFase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RekruttererFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
CD4CAR for CD4+ Leukemia and Lymphoma
RekruttererFase 1
- Albert Einstein Health Network, New York
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
RekruttererFase 1/2
- Memorial Sloan Kettering, New York
A Registry for People With T-cell Lymphoma
RekruttererObservasjonsstudie
- Weill Cornell Medical Center (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
RekruttererFase 2
- Icahn School of Medicine at Mount Sinai, New York
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
RekruttererFase 1
- Columbia University Irving Medical Center, New York
Tissue Repository: CTCL Collection Protocol
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Columbia University Irving Medical Center, New York
MB-105 in Patients With CD5 Positive T-cell Lymphoma
RekruttererFase 2
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RekruttererFase 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
T-celle-lymfom-studier i andre byer
- Philadelphia, PA10 studier
- Baldwin Park, CA9 studier
- Boston, MA9 studier
- Houston, TX8 studier
- Atlanta, GA8 studier
- Rochester, MN6 studier
- Columbus, OH6 studier
- Chicago, IL6 studier
- Seattle, WA6 studier
- New Haven, CT5 studier
- Miami, FL5 studier
- Scottsdale, AZ4 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.